Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Christina Finlayson

Concepts (200)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
26
2017
2418
0.880
Why?
Carcinoma, Ductal, Breast
5
2017
92
0.450
Why?
Mastectomy, Segmental
5
2017
107
0.360
Why?
Receptors, Estrogen
7
2012
406
0.310
Why?
Sentinel Lymph Node Biopsy
3
2008
118
0.280
Why?
Lymph Nodes
3
2007
511
0.280
Why?
Thoracic Vertebrae
1
2007
90
0.250
Why?
Prostheses and Implants
1
2007
137
0.240
Why?
Mammography
1
2007
175
0.230
Why?
Receptors, Progesterone
4
2012
242
0.210
Why?
src Homology Domains
1
2003
34
0.200
Why?
Mastectomy
3
2007
189
0.180
Why?
Estrogens
3
2012
364
0.180
Why?
Preoperative Care
2
2001
396
0.170
Why?
Patients
1
2001
183
0.150
Why?
Phytotherapy
1
2000
74
0.150
Why?
Vitamin E
1
2000
123
0.150
Why?
Postoperative Hemorrhage
1
2000
106
0.140
Why?
Mammaplasty
1
2001
150
0.140
Why?
Counseling
1
2001
406
0.140
Why?
Neoplasm Staging
8
2010
1488
0.130
Why?
Tamoxifen
5
2012
193
0.130
Why?
Reoperation
2
2017
645
0.130
Why?
Pelvic Exenteration
1
1996
12
0.120
Why?
Pelvic Neoplasms
1
1996
24
0.120
Why?
Neoplasms, Radiation-Induced
1
2016
100
0.120
Why?
Neoplasms, Second Primary
1
2016
103
0.110
Why?
Neoadjuvant Therapy
3
2010
475
0.110
Why?
Carcinoma, Lobular
2
2017
59
0.110
Why?
Risk Reduction Behavior
1
2016
220
0.110
Why?
Hodgkin Disease
1
2016
173
0.110
Why?
Antineoplastic Agents, Hormonal
4
2012
196
0.100
Why?
Gene Expression Regulation, Neoplastic
3
2010
1432
0.100
Why?
Signal Transduction
3
2012
5246
0.090
Why?
Insulin
1
2003
2525
0.090
Why?
Neoplasms, Hormone-Dependent
1
2012
33
0.090
Why?
Radiotherapy, Adjuvant
3
2008
222
0.090
Why?
Practice Patterns, Physicians'
2
2017
1408
0.090
Why?
Breast
2
2003
155
0.080
Why?
Carcinoma in Situ
1
2011
45
0.080
Why?
Axilla
2
2007
51
0.080
Why?
Female
23
2017
79499
0.080
Why?
Practice Guidelines as Topic
2
2017
1591
0.080
Why?
Keratin-5
1
2010
43
0.080
Why?
Radiotherapy
2
2008
209
0.080
Why?
BRCA2 Protein
1
2009
69
0.070
Why?
Pregnancy Complications, Neoplastic
1
2009
64
0.070
Why?
Estrogen Receptor alpha
1
2010
154
0.070
Why?
Thrombophilia
1
2009
89
0.070
Why?
Humans
30
2017
146342
0.070
Why?
Middle Aged
14
2017
36619
0.070
Why?
Aromatase Inhibitors
1
2008
81
0.060
Why?
Drug Resistance, Neoplasm
2
2010
893
0.060
Why?
Palliative Care
1
1996
1032
0.060
Why?
Adjuvants, Immunologic
1
2008
245
0.060
Why?
Breast Cyst
1
2006
2
0.060
Why?
Cyst Fluid
1
2006
20
0.060
Why?
Radiotherapy Planning, Computer-Assisted
1
2007
150
0.060
Why?
Carcinoma, Papillary
1
2007
83
0.060
Why?
Sternum
1
2006
26
0.060
Why?
Phosphoproteins
2
2008
320
0.060
Why?
Biomarkers, Tumor
2
2010
1339
0.060
Why?
Melatonin
1
2006
165
0.060
Why?
Carcinoma, Ductal
1
2005
10
0.060
Why?
Ki-67 Antigen
1
2005
120
0.050
Why?
Enzyme Inhibitors
1
2008
823
0.050
Why?
Combined Modality Therapy
4
2008
1271
0.050
Why?
Adult
12
2017
41087
0.050
Why?
Retroviridae Proteins, Oncogenic
1
2003
10
0.050
Why?
Oncogene Protein v-akt
1
2003
24
0.050
Why?
Insulin Receptor Substrate Proteins
1
2003
55
0.050
Why?
Bone Neoplasms
1
2006
272
0.050
Why?
Receptor, Insulin
1
2003
92
0.050
Why?
rhoA GTP-Binding Protein
1
2003
76
0.050
Why?
Multiple Sclerosis
1
2008
435
0.050
Why?
Liver Neoplasms
1
2009
776
0.050
Why?
Proto-Oncogene Proteins p21(ras)
1
2003
250
0.050
Why?
Vascular Endothelial Growth Factor A
1
2005
545
0.050
Why?
Mitogen-Activated Protein Kinases
1
2003
288
0.050
Why?
Urachus
1
2002
1
0.040
Why?
Retrospective Studies
5
2017
17438
0.040
Why?
Referral and Consultation
1
2007
881
0.040
Why?
Mastectomy, Radical
1
2000
4
0.040
Why?
Nurse Anesthetists
1
2000
7
0.040
Why?
Neoplasm Recurrence, Local
1
2007
1160
0.040
Why?
Aged
6
2017
26432
0.040
Why?
Prospective Studies
2
2003
8123
0.040
Why?
Tomography, X-Ray Computed
2
2007
2786
0.040
Why?
Phosphorylation
1
2003
1724
0.040
Why?
Gynecomastia
1
1998
6
0.040
Why?
Immunohistochemistry
3
2008
1712
0.040
Why?
Cluster Analysis
2
2012
496
0.040
Why?
Urinary Bladder Neoplasms
1
2002
259
0.040
Why?
Endocrine System Diseases
1
1998
35
0.030
Why?
Blood Coagulation
1
2000
267
0.030
Why?
Oligonucleotide Array Sequence Analysis
2
2012
752
0.030
Why?
Survival Rate
2
2008
2092
0.030
Why?
Margins of Excision
1
2017
55
0.030
Why?
Apoptosis
2
2010
2439
0.030
Why?
Gene Expression Profiling
3
2008
1792
0.030
Why?
Ultrasonography
1
2000
788
0.030
Why?
Consensus
1
2017
467
0.030
Why?
Estradiol
2
2010
517
0.030
Why?
Quality Indicators, Health Care
1
2017
343
0.030
Why?
Aged, 80 and over
2
2010
8391
0.030
Why?
Lymph Node Excision
2
2009
174
0.030
Why?
Decision Making
1
2001
993
0.030
Why?
Adenocarcinoma
1
2000
927
0.020
Why?
Guideline Adherence
1
2017
594
0.020
Why?
CD24 Antigen
1
2012
18
0.020
Why?
Breast Neoplasms, Male
1
2012
29
0.020
Why?
Hyaluronan Receptors
1
2012
105
0.020
Why?
Patient Selection
1
1996
728
0.020
Why?
Mice, SCID
1
2012
360
0.020
Why?
Tumor Burden
1
2012
326
0.020
Why?
Colorado
2
2017
4595
0.020
Why?
Clinical Trials as Topic
1
1996
1064
0.020
Why?
Tumor Cells, Cultured
1
2012
882
0.020
Why?
Biopsy, Needle
1
2011
183
0.020
Why?
Mice, Inbred NOD
1
2012
598
0.020
Why?
Cell Line, Tumor
2
2010
3545
0.020
Why?
Mass Screening
1
1998
1307
0.020
Why?
Peptide Mapping
1
2010
61
0.020
Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
109
0.020
Why?
Gene Regulatory Networks
1
2012
319
0.020
Why?
Databases, Protein
1
2010
88
0.020
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
143
0.020
Why?
Prognosis
2
2009
4351
0.020
Why?
Pregnancy Trimester, Second
1
2009
91
0.020
Why?
Xenograft Model Antitumor Assays
1
2012
930
0.020
Why?
Observer Variation
1
2010
356
0.020
Why?
Glatiramer Acetate
1
2008
11
0.020
Why?
Interferon beta-1a
1
2008
12
0.020
Why?
Pregnancy Trimester, First
1
2009
140
0.020
Why?
Cyclophosphamide
1
2009
275
0.020
Why?
Apoptosis Regulatory Proteins
1
2009
186
0.020
Why?
Databases as Topic
1
2008
70
0.020
Why?
Estrogen Receptor Modulators
1
2008
14
0.020
Why?
Perilipin-1
1
2008
16
0.020
Why?
Neoplastic Stem Cells
1
2012
403
0.020
Why?
S100 Proteins
1
2008
33
0.020
Why?
Neoplasm Invasiveness
1
2010
504
0.020
Why?
Interferon-beta
1
2008
90
0.020
Why?
Androstadienes
1
2008
77
0.020
Why?
Perimenopause
1
2008
69
0.020
Why?
Mastectomy, Modified Radical
1
2007
6
0.020
Why?
In Situ Hybridization, Fluorescence
1
2008
334
0.020
Why?
SEER Program
1
2008
233
0.020
Why?
Blotting, Western
1
2010
1177
0.020
Why?
Lymphatic Metastasis
1
2008
335
0.020
Why?
Selective Estrogen Receptor Modulators
1
2007
33
0.020
Why?
Carcinoma, Intraductal, Noninfiltrating
1
2007
61
0.020
Why?
Doxorubicin
1
2009
416
0.020
Why?
Dehydroepiandrosterone Sulfate
1
2006
43
0.020
Why?
Mice, Nude
1
2008
668
0.010
Why?
Epidermal Growth Factor
1
2006
157
0.010
Why?
Transcriptome
1
2012
1068
0.010
Why?
Positron-Emission Tomography
1
2006
343
0.010
Why?
Neoplasm Proteins
1
2007
444
0.010
Why?
Neoplasms
1
2000
2954
0.010
Why?
Transforming Growth Factor beta
1
2006
467
0.010
Why?
Carrier Proteins
1
2008
728
0.010
Why?
Patient Care Planning
1
2005
170
0.010
Why?
Chemotherapy, Adjuvant
1
2005
429
0.010
Why?
Quality of Life
1
1996
3200
0.010
Why?
Antineoplastic Agents
2
2008
2219
0.010
Why?
Diagnosis, Differential
1
2007
1503
0.010
Why?
Cell Proliferation
1
2010
2502
0.010
Why?
Proteomics
1
2010
1203
0.010
Why?
Mice
2
2012
18297
0.010
Why?
Postmenopause
1
2005
394
0.010
Why?
Peptides
1
2008
992
0.010
Why?
Treatment Outcome
1
2017
11821
0.010
Why?
Umbilicus
1
2002
18
0.010
Why?
Phenotype
1
2010
3206
0.010
Why?
Abdominal Neoplasms
1
2002
48
0.010
Why?
Reproducibility of Results
1
2010
3416
0.010
Why?
Biopsy
1
2005
1075
0.010
Why?
Age Factors
1
2008
3347
0.010
Why?
Liver
1
2009
1864
0.010
Why?
Hospitals, Private
1
1999
12
0.010
Why?
Hospitals, County
1
1999
11
0.010
Why?
United States
1
2017
16136
0.010
Why?
Receptors, Tumor Necrosis Factor
1
2000
162
0.010
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2009
1998
0.010
Why?
Hospitals, University
1
1999
178
0.010
Why?
Leydig Cell Tumor
1
1998
8
0.010
Why?
Male
4
2012
73396
0.010
Why?
Animals
2
2012
38107
0.010
Why?
Infant, Newborn
1
2009
6460
0.010
Why?
Testicular Neoplasms
1
1998
108
0.010
Why?
Pregnancy
1
2009
7230
0.010
Why?
NF-kappa B
1
2000
674
0.010
Why?
Cost-Benefit Analysis
1
1998
640
0.010
Why?
Tumor Necrosis Factor-alpha
1
2000
1224
0.010
Why?
Socioeconomic Factors
1
1999
1327
0.010
Why?
Patient Education as Topic
1
1999
770
0.010
Why?
Risk Factors
1
2008
10921
0.010
Why?
Models, Biological
1
2000
1761
0.010
Why?
Adolescent
1
1998
22557
0.000
Why?
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)